Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma-Reference-Cited by-同舟云学术

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

Published:2005 Issue:4 Volume:104 Page:682-691
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pusztai Lajos,Wagner Peter,Ibrahim Nuhad,Rivera Edgardo,Theriault Richard,Booser Daniel,Symmans Fraser W.,Wong Franklin,Blumenschein George,Fleming Donald R.,Rouzier Roman,Boniface Graeme,Hortobagyi Gabriel N.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. Multidrug resistance in cancer: role of ATP–dependent transporters

2. Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional Significance

3. P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer

Cited by 253 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lathyrane diterpenoids with multidrug resistance reversal activity from the tubers of Euphorbia antiquorum;Phytochemistry;2024-12

2. Role of P-glycoprotein in Regulating the Efficacy, Toxicity and Pharmacokinetics of Yunaconitine;Current Drug Metabolism;2024-08-06

3. Discovery of oral chemotherapeutic reversal agents for treating multidrug resistance cancer;European Journal of Pharmacology;2024-08

4. Strategies to enhance the response of liver cancer to pharmacological treatments;American Journal of Physiology-Cell Physiology;2024-07-01

5. Tolerability of tariquidar – A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsy;Seizure: European Journal of Epilepsy;2024-07